Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

30.55USD
23 Apr 2018
Change (% chg)

$-0.60 (-1.93%)
Prev Close
$31.15
Open
$31.00
Day's High
$31.10
Day's Low
$30.10
Volume
128,164
Avg. Vol
283,146
52-wk High
$32.60
52-wk Low
$12.70

Select another date:

Wed, Mar 28 2018

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

Select another date: